MedPharm || طبصيدلة

35-year-old female with stage II breast cancer. Which one of the following effective initial adjuvant chemotherapy regimens should be offered to her following mastectomy? a- Doxorubicin alone b- Doxorubicin and epirubicin c- Doxorubicin and epirubicin with the addition of paclitaxel d- Doxorubicin and epirubicin with the addition of trastuzumab e- No chemotherapy is recommended at this stage.

In metastatic breast cancer (stage IV), we consider adding agents to standard therapy for treating breast cancer patients with metastases to the bone to decrease rates of skeletal-related events, such as fractures, spinal cord compression, and pain, and the need for radiation to the bones or surgery. Which medication is frequently added ?

The best primary management for a patient with extensive nodal involvement- breast carcinoma is: A. Fluorouracil, doxorubicin, cyclophosphamide without surgical removal B. Fluorouracil, doxorubicin, cyclophosphamide before surgical removal C. Fluorouracil, doxorubicin, cyclophosphamide after surgical removal D. Surgical removal only

A 38-year-old premenopausal woman has just undergone breast-conserving surgery for Stage I breast cancer. Her tumor is Estrogen Receptor positive (ER+), Progesterone Receptor positive (PR+), and HER2-negative. She is preparing to start adjuvant endocrine therapy. Which of the following is the generally preferred initial agent for this patient? A) Letrozole B) Anastrozole C) Tamoxifen D) Fulvestrant E) Exemestane

A 42-year-old woman presents with metastatic breast cancer. Biopsy results show her tumor is ER-negative, PR-negative, and HER2-negative (Triple-Negative Breast Cancer). She lacks germline BRCA mutations and PD-L1 expression is low. What is the most appropriate initial systemic treatment strategy? A) Endocrine therapy with an Aromatase Inhibitor B) Pembrolizumab plus chemotherapy C) Cytotoxic chemotherapy D) Ado-trastuzumab emtansine E) Endocrine therapy and Pembrolizumab

A 62-year-old postmenopausal woman is diagnosed with early-stage breast cancer. Pathology reports indicate the tumor is Estrogen Receptor positive (ER+), Progesterone Receptor positive (PR+), and HER2-negative. After surgical resection and adjuvant chemotherapy, which of the following is the most appropriate adjuvant endocrine therapy? A) Tamoxifen B)Anstrazole C) Trastuzumab D) Fulvestrant E)Neratinib

Which drug is combined with trastuzumab and a taxane as the preferred first-line option for HER2-overexpressing metastatic breast cancer? A) Lapatinib B) Neratinib C) Pertuzumab D) Tucatinib E) Ado-trastuzumab emtansine